Haemaccel (Polygeline)

Haemaccel is indicated for the management of conditions that involve reduced circulating blood volume.

• Acute hypovolemia resulting from hemorrhage or fluid loss
• Shock states where rapid plasma volume expansion is required
• Surgical blood loss during major operative procedures
• Severe burns with extensive fluid shifts
• Trauma patients with significant fluid deficits

Adverse reactions to Haemaccel are generally related to its colloid nature and the infusion process.

Common

• Transient hypotension or blood pressure fluctuations
• Flushing or feeling of warmth
• Mild fever or chills
• Nausea or mild gastrointestinal discomfort
• Headache or dizziness
• Pain or irritation at the injection site

Serious

• Anaphylactic or severe allergic reactions
• Marked hypotension leading to cardiovascular compromise
• Pulmonary edema due to fluid overload
• Hemolysis or red blood cell destruction
• Acute renal impairment or failure
• Coagulopathy or bleeding disorders

When using Haemaccel, clinicians should consider several safety measures to minimize risk.

• Assess patient volume status and cardiac function before infusion
• Use caution in patients with known hypersensitivity to polygeline or gelatin derivatives
• Monitor vital signs and urine output throughout administration
• Adjust infusion rate in individuals with compromised renal or hepatic function
• Avoid rapid bolus administration; prefer controlled infusion
• Evaluate for signs of fluid overload, especially in heart failure patients
• Pregnancy and lactation status should be confirmed, as safety data are limited

Haemaccel may interact with other agents that affect fluid balance, coagulation, or immune response.

Avoid

• Concurrent use of other colloid solutions that may cause cumulative volume overload
• High-dose diuretics that could exacerbate hypovolemia when combined with rapid infusion
• Agents known to trigger severe allergic reactions in gelatin-sensitive patients

Use with caution

• Blood products or plasma expanders that alter coagulation parameters
• Vasopressors, as rapid volume changes can affect their efficacy
• Nephrotoxic drugs, due to potential additive renal stress
• Anticoagulants, because plasma expanders may influence bleeding risk